PUBLIKATIONSLISTE (Stand 26.04.2009)
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.
Pichler M, Balic M, Stadelmeyer E, Ausch C, Wild M, Guelly C, Bauernhofer T, Samonigg H, Hoefler G, Dandachi N. J Mol Diagn. 2009; 11(2):140-7.
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators, Marth C. N Engl J Med. 2009; 360(7):679-91.
Optimization of diagnostic ELISA-based tests for the detection of auto-antibodies against tumor antigens in human serum.
Stefatic, D; Riederer, M; Balic, M; Dandachi, N; Stanzer, S; Janesch, B; Resel, M; Ler, D; Samonigg, H; Bauernhofer, T. Bosn J Basic Med Sci. 2008; 8(3): 245-250.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Lancet Oncol. 2008; 9(9):840-9.
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Clin Cancer Res. 2008; 14(7):2082-7.
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M; Austrian Breast and Colorectal Cancer Study Group. Clin Cancer Res. 2008;14(6):1767-74.
Expansion and resistance to apoptosis of CD4+CD25+high regulatory T cells in patients with metastatic epithelial cancer.
Stanzer S., Dandachi N., Balic M., Resel M., Samonigg H., Bauernhofer T. J Clin Immunol. 2008; 28(2):107-14. Epub 2007 Oct 16.
The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline based neoadjuvant chemotherapy of breast cancer.
Schippinger W., Dandachi N., Regitnig P., Hofmann G., Balic M., Neumann R., Samonigg H., Bauernhofer T. J Am Clin Pathol 2007; 128(4):630-7.
Immunomagnetic CD45 Depletion does not improve CK20 RT-PCR in Colorectal Cancer.
Ausch C., Dandachi N., Buxhofer-Ausch V., Balic M., Bauernhofer T., Garschall K., Huber K., Hinterberger W., Braun S., Schiessel R. Clin Chem Lab Med. 2007; 45(3):351-6.
Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoids tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
Liegl B, Leithner A, Bauernhofer T, Windhager R, Guelly C, Regauer S, Beham A. Histopathology. 2006 Dec;49(6):576-81.
Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer.
Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F. Virchows Arch. 2006; 449(1):24-30.
Plasmapheresis reverses all side-effects of a cisplatin overdose--a case report and treatment recommendation.
Hofmann G, Bauernhofer T, Krippl P, Lang-Loidolt D, Horn S, Goessler W, Schippinger W, Ploner F, Stoeger H, Samonigg H. BMC Cancer. 2006; 6:1.
Recurrent endometrial stromal sarcoma after treatment with high-dose chemotherapy and autologous stem-cell support: A case report.
Klaritsch P, Reich O, Regauer S, Bauernhofer T. Eur J Gynaecol Oncol. 2006;27(3):297-8.
Frequency of Febrile Neutropenia in Breast Cancer Patients Receiving Epirubicin and Docetaxel/Paclitaxel with Colony-Stimulating Growth Factors: A Comparison of Filgrastim or Lenograstim with Pegfilgrastim.
Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H. Oncology (Basel). 2006; 70(4):290-293.
Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT.
Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, Schoellnast H, Preidler KW, Samonigg H. Radiology. 2005 Feb; 234(2):479-85.
Comparison of two methods for enumerating circulating tumor cells in carcinoma patients.
M. Balic, N. Dandachi, G. Hofmann, H. Samonigg, H. Loibner, A. Obwaller, A. van der Kooi, A. Tibbe, GV. Doyle, LWMM Terstappen, T. Bauernhofer. Cytometry Part B 2005; 68B:25-30.
Critical evaluation of CK 20 real time PCR for the detection of micrometastases in the peripheral blood of patients with colorectal cancer.
N. Dandachi N, Balic M, Stanzer S, Halm M, Resel M, Hinterleitner TA, Samonigg H, Bauernhofer T. J Mol Diagnostics 2005; 7:631-637.
Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer.
Bauernhofer T, Zenahlik S, Hofmann G, Balic M, Resel M, Pirchmoser R, Regitnig P, Ambros P, Dandachi N, Samonigg H. Oncol Rep. 2005 Feb;13(2):179-84.
The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W, Regitnig P, Bauernhofer T, Ploner F, Hofmann G, Krippl P, Wehrschutz M, Lax S, Carney W, Neumann R, Wernecke KD, Samonigg H. Oncol Rep. 2004 Jun;11(6):1331-6.
Acute pseudo-obstruction of the small intestine following high-dose chemotherapy and stem cell transplantation T. Bauernhofer, M. Eibl, F. Ploner, I. Kuss, J. Pfeifer, H. Sill, H. Samonigg. Onkologie, 2003; 26:344-346.
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And Colorectal Cancer Study Group. Onkologie. 2003 Apr;26(2):115-9.
Preferential apoptosis of CD56+dim natural killer cell subset in patients with cancer. T. Bauernhofer, I. Kuss, B. Henderson, AS. Baum, TL. Whiteside. European Journal of Immunology 2003; 33:119-124.
The role of CD25 and prolactin receptor expression in the protection of circulating T lymphocytes from apoptosis in patients with breast cancer. T. Bauernhofer, I. Kuss, U. Friebe-Hoffmann, G. Dworacki, A. S. Baum, B. Vonderhaar, TL. Whiteside. British Journal of Cancer 2003; 88(8): 1301-1309.